Drug class
Hepatitis C virus (HCV) NS3/4A protease inhibitor; direct-acting antiviral
Mechanism of action
Inhibits the HCV NS3/4A serine protease, which is required to cleave the viral polyprotein into mature non-structural proteins essential for viral replication.
General use cases
- Treatment of chronic hepatitis C infection in combination with elbasvir for the genotypes and patient groups specified in the applicable product label.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
